Literature DB >> 30348770

Cocaine reward is reduced by decreased expression of receptor-type protein tyrosine phosphatase D (PTPRD) and by a novel PTPRD antagonist.

George R Uhl1,2,3,4,5,6,7,8,9, Maria J Martinez10,5, Paul Paik9, Agnieszka Sulima11, Guo-Hua Bi12, Malliga R Iyer11, Eliot Gardner13, Kenner C Rice11, Zheng-Xiong Xi12.   

Abstract

Receptor-type protein tyrosine phosphatase D (PTPRD) is a neuronal cell-adhesion molecule/synaptic specifier that has been implicated in addiction vulnerability and stimulant reward by human genomewide association and mouse cocaine-conditioned place-preference data. However, there have been no reports of effects of reduced expression on cocaine self-administration. There have been no reports of PTPRD targeting by any small molecule. There are no data about behavioral effects of any PTPRD ligand. We now report (i) robust effects of heterozygous PTPRD KO on cocaine self-administration (These data substantially extend prior conditioned place-preference data and add to the rationale for PTPRD as a target for addiction therapeutics.); (ii) identification of 7-butoxy illudalic acid analog (7-BIA) as a small molecule that targets PTPRD and inhibits its phosphatase with some specificity; (iii) lack of toxicity when 7-BIA is administered to mice acutely or with repeated dosing; (iv) reduced cocaine-conditioned place preference when 7-BIA is administered before conditioning sessions; and (v) reductions in well-established cocaine self-administration when 7-BIA is administered before a session (in WT, not PTPRD heterozygous KOs). These results add to support for PTPRD as a target for medications to combat cocaine use disorders. 7-BIA provides a lead compound for addiction therapeutics.

Entities:  

Keywords:  Post-GWAS; addiction; cell adhesion molecule; drug discovery; stimulant use disorder

Mesh:

Substances:

Year:  2018        PMID: 30348770      PMCID: PMC6233130          DOI: 10.1073/pnas.1720446115

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  41 in total

1.  NrCAM in addiction vulnerability: positional cloning, drug-regulation, haplotype-specific expression, and altered drug reward in knockout mice.

Authors:  Hiroki Ishiguro; Qing-Rong Liu; Jian-Ping Gong; Frank Scott Hall; Hiroshi Ujike; Marisela Morales; Takeshi Sakurai; Martin Grumet; George R Uhl
Journal:  Neuropsychopharmacology       Date:  2006-03       Impact factor: 7.853

2.  Addiction molecular genetics: 639,401 SNP whole genome association identifies many "cell adhesion" genes.

Authors:  Qing-Rong Liu; Tomas Drgon; Catherine Johnson; Donna Walther; Judith Hess; George R Uhl
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2006-12-05       Impact factor: 3.568

3.  Cell adhesion molecules: druggable targets for modulating the connectome and brain disorders?

Authors:  George R Uhl; Jana Drgonova
Journal:  Neuropsychopharmacology       Date:  2014-01       Impact factor: 7.853

4.  Genome-wide association study of copy number variations (CNVs) with opioid dependence.

Authors:  Dawei Li; Hongyu Zhao; Henry R Kranzler; Ming D Li; Kevin P Jensen; Tetyana Zayats; Lindsay A Farrer; Joel Gelernter
Journal:  Neuropsychopharmacology       Date:  2014-09-27       Impact factor: 7.853

Review 5.  Cyclin dependent kinase 5: A novel avenue for Alzheimer's disease.

Authors:  Anisha S Bhounsule; Lokesh Kumar Bhatt; Kedar S Prabhavalkar; Manisha Oza
Journal:  Brain Res Bull       Date:  2017-05-17       Impact factor: 4.077

6.  Increased activity of cyclin-dependent kinase 5 leads to attenuation of cocaine-mediated dopamine signaling.

Authors:  Satoru Takahashi; Toshio Ohshima; Andrew Cho; Taduru Sreenath; Michael J Iadarola; Harish C Pant; Yong Kim; Angus C Nairn; Roscoe O Brady; Paul Greengard; Ashok B Kulkarni
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-21       Impact factor: 11.205

7.  Trans-synaptic adhesions between netrin-G ligand-3 (NGL-3) and receptor tyrosine phosphatases LAR, protein-tyrosine phosphatase delta (PTPdelta), and PTPsigma via specific domains regulate excitatory synapse formation.

Authors:  Seok-Kyu Kwon; Jooyeon Woo; Soo-Young Kim; Hyun Kim; Eunjoon Kim
Journal:  J Biol Chem       Date:  2010-02-06       Impact factor: 5.157

8.  Cadherin 13: human cis-regulation and selectively-altered addiction phenotypes and cerebral cortical dopamine in knockout mice.

Authors:  Jana Drgonova; Donna Walther; G Luke Hartstein; Mohammad O Bukhari; Michael H Baumann; Jonathan Katz; Frank Scott Hall; Elizabeth R Arnold; Shaun Flax; Anthony Riley; Olga Rivero-Martin; Klaus-Peter Lesch; Juan Troncoso; Barbara Ranscht; George R Uhl
Journal:  Mol Med       Date:  2016-08-18       Impact factor: 6.354

9.  Genome-wide association for methamphetamine dependence: convergent results from 2 samples.

Authors:  George R Uhl; Tomas Drgon; Qing-Rong Liu; Catherine Johnson; Donna Walther; Tokutaro Komiyama; Mutsuo Harano; Yoshimoto Sekine; Toshiya Inada; Norio Ozaki; Masaomi Iyo; Nakao Iwata; Mitsuhiko Yamada; Ichiro Sora; Chih-Ken Chen; Hsing-Cheng Liu; Hiroshi Ujike; Shih-Ku Lin
Journal:  Arch Gen Psychiatry       Date:  2008-03

10.  Genome-wide analysis in UK Biobank identifies four loci associated with mood instability and genetic correlation with major depressive disorder, anxiety disorder and schizophrenia.

Authors:  Joey Ward; Rona J Strawbridge; Mark E S Bailey; Nicholas Graham; Amy Ferguson; Donald M Lyall; Breda Cullen; Laura M Pidgeon; Jonathan Cavanagh; Daniel F Mackay; Jill P Pell; Michael O'Donovan; Valentina Escott-Price; Daniel J Smith
Journal:  Transl Psychiatry       Date:  2017-11-30       Impact factor: 6.222

View more
  11 in total

1.  Synthesis of illudalic acid and analogous phosphatase inhibitors.

Authors:  Harvey F Fulo; Nicole J Rueb; Robert Gaston; Paratchata Batsomboon; Kh Tanvir Ahmed; Amy M Barrios; Gregory B Dudley
Journal:  Org Biomol Chem       Date:  2021-12-15       Impact factor: 3.876

2.  Structure-activity studies of PTPRD phosphatase inhibitors identify a 7-cyclopentymethoxy illudalic acid analog candidate for development.

Authors:  Ian M Henderson; Fanxun Zeng; Nazmul H Bhuiyan; Dan Luo; Maria Martinez; Jane Smoake; Fangchao Bi; Chamani Perera; David Johnson; Thomas E Prisinzano; Wei Wang; George R Uhl
Journal:  Biochem Pharmacol       Date:  2021-12-02       Impact factor: 6.100

3.  Genome-wide association analyses of symptom severity among clozapine-treated patients with schizophrenia spectrum disorders.

Authors:  C Okhuijsen-Pfeifer; M Z van der Horst; C A Bousman; B Lin; K R van Eijk; S Ripke; Y Ayhan; M O Babaoglu; M Bak; W Alink; H van Beek; E Beld; A Bouhuis; M Edlinger; I M Erdogan; A Ertuğrul; G Yoca; I P Everall; T Görlitz; K P Grootens; S Gutwinski; T Hallikainen; E Jeger-Land; M de Koning; M Lähteenvuo; S E Legge; S Leucht; C Morgenroth; A Müderrisoğlu; A Narang; C Pantelis; A F Pardiñas; T Oviedo-Salcedo; J Schneider-Thoma; S Schreiter; E Repo-Tiihonen; H Tuppurainen; M Veereschild; S Veerman; M de Vos; E Wagner; D Cohen; J P A M Bogers; J T R Walters; A E Anil Yağcıoğlu; J Tiihonen; A Hasan; J J Luykx
Journal:  Transl Psychiatry       Date:  2022-04-07       Impact factor: 7.989

Review 4.  PTPRD: neurobiology, genetics, and initial pharmacology of a pleiotropic contributor to brain phenotypes.

Authors:  George R Uhl; Maria J Martinez
Journal:  Ann N Y Acad Sci       Date:  2019-01-15       Impact factor: 5.691

5.  Genome-wide association study identifies a novel maternal gene × stress interaction associated with spontaneous preterm birth.

Authors:  Xiumei Hong; Pamela J Surkan; Boyang Zhang; Amaris Keiser; Yuelong Ji; Hongkai Ji; Irina Burd; Blandine Bustamante-Helfrich; S Michelle Ogunwole; Wan-Yee Tang; Li Liu; Colleen Pearson; Sandra Cerda; Barry Zuckerman; Lingxin Hao; Xiaobin Wang
Journal:  Pediatr Res       Date:  2020-07-29       Impact factor: 3.756

6.  Splice-dependent trans-synaptic PTPδ-IL1RAPL1 interaction regulates synapse formation and non-REM sleep.

Authors:  Haram Park; Yeonsoo Choi; Hwajin Jung; Seoyeong Kim; Suho Lee; Hyemin Han; Hanseul Kweon; Suwon Kang; Woong Seob Sim; Frank Koopmans; Esther Yang; Hyun Kim; August B Smit; Yong Chul Bae; Eunjoon Kim
Journal:  EMBO J       Date:  2020-04-29       Impact factor: 11.598

7.  Behavioral and neurological analyses of adult mice carrying null and distinct loss-of-receptor function mutations in protein tyrosine phosphatase receptor type Z (PTPRZ).

Authors:  Naomi Tanga; Kazuya Kuboyama; Ayako Kishimoto; Miho Kihara; Hiroshi Kiyonari; Toshio Watanabe; Akihiro Fujikawa; Masaharu Noda
Journal:  PLoS One       Date:  2019-06-13       Impact factor: 3.240

8.  Protein Tyrosine Phosphatase Receptor Type D Regulates Neuropathic Pain After Nerve Injury via the STING-IFN-I Pathway.

Authors:  Chengkuan Sun; Guangzhi Wu; Zhan Zhang; Rangjuan Cao; Shusen Cui
Journal:  Front Mol Neurosci       Date:  2022-04-14       Impact factor: 5.639

Review 9.  A Novel Precision Approach to Overcome the "Addiction Pandemic" by Incorporating Genetic Addiction Risk Severity (GARS) and Dopamine Homeostasis Restoration.

Authors:  Kenneth Blum; Shan Kazmi; Edward J Modestino; Bill William Downs; Debasis Bagchi; David Baron; Thomas McLaughlin; Richard Green; Rehan Jalali; Panayotis K Thanos; Igor Elman; Rajendra D Badgaiyan; Abdalla Bowirrat; Mark S Gold
Journal:  J Pers Med       Date:  2021-03-16

10.  Genetic contributions to alcohol use disorder treatment outcomes: a genome-wide pharmacogenomics study.

Authors:  Joanna M Biernacka; Brandon J Coombes; Anthony Batzler; Ada Man-Choi Ho; Jennifer R Geske; Josef Frank; Colin Hodgkinson; Michelle Skime; Colin Colby; Lea Zillich; Sofia Pozsonyiova; Ming-Fen Ho; Falk Kiefer; Marcella Rietschel; Richard Weinshilboum; Stephanie S O'Malley; Karl Mann; Ray Anton; David Goldman; Victor M Karpyak
Journal:  Neuropsychopharmacology       Date:  2021-07-23       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.